2024-07-10 16:50:00
New research highlights the importance of diagnosing prostate cancer early enough to intervene and reduce the risk of death. Recently, some experts have called for a lower stage of prostate cancer to be reclassified as benign, but many patients may have more aggressive cancer than biopsy alone suggests.
A new study led by a researcher at the Mass. General Brigham Al analyzed data from more than 10,000 patients at a university in Germany, and found that less than 8% of patients had a low percentage in the way very aggressive prostate cancer. They also found that many high-risk GGG1 patients can be identified based on high PSA levels or having 50% or more of their biopsy samples test positive.
The study identified risk factors that help determine which patients with GGG1 are at greater risk of suffering from aggressive disease and death. For patients with GGG1 who are at high risk, we should continue to call their cancer diagnosis and do it based on this information. In the case of GGG1 patients who do not have any of these risk factors, the probability of death is very low. But for doctors who treat patients at the highest risk, the message is clear: Call it cancer and take a hard look.
Of the 10,228 patients in the study group, pathology (ie, high Gleason group score or positive pelvic lymph nodes) at the time of radical prostatectomy was found in 955 of the 9,248 patients evaluated by TRUS (10.33%) and in 77 of 980 patients examined using the combined biopsy method (7.86%).
About 6% of GGG1 patients have a PSA level of 20 ng/ml or higher, and 12 to 14% of GGG1 patients have more than half of their routine biopsies test positive. Patients with any of these indicators have a significantly higher risk of pathology, risk of early PSA failure, and risk of death.
The authors note the possible limitations of their study, including that the study population was from a single institution, pre-diagnosis PSA levels were not available, and many patients had samples collected and analyzed before enough combined biopsy widely and diagnostic guidelines will be updated 2014. However, the researchers found the same result for predicting a higher risk of poor pathology and early repair (within 18 months) with removal of the prostate in patients who we check with both methods.
For patients with GGG1 who have one or both of these increased risk indicators, there are steps doctors can take, such as performing an early follow-up biopsy or recommending genetic testing, to evaluate for aggressive prostate cancer. it was not found in the first biopsy. to be able to intervene earlier and reduce the risk of aggressive disease and death. Improving cancer classification for high-risk patients can improve their treatment plan and reduce the risk of death.
The results are published in the European journal Urology Oncology.
#Risks #underdiagnosed #prostate #cancer